So far it has been shown that sitagliptin improves fatty liver [24, 25], that GIP contributes to bone metabolism [26, 27], and, from a meta-analysis, that the risk of bone fracture is significantly reduced in patients treated with DPP-4 inhibitors [28]. This evidence concerns the gene GIP and bone fracture.